Fig. 6

The mass characteristic frequency measured before NACT, at the mid-course of NACT, and after NACT but before surgery for different molecular subtypes: a–c Luminal A type, d–f Luminal B (HER2-) type, g–i Luminal B (HER2+) type, j–l HER2+ type, and m–o TN type. NACT, neoadjuvant chemotherapy; TN, triple-negative